CL2012003462A1 - Composicion fluida injectable que comprende al menos un polimero termoplastico biodegradable, un liquido organico aprotico polar biocompatible y buprenorfina, donde la composicion es transformada in situ en un implante solido por contacto con agua u otro medio; método para prepararla; implante y kit. - Google Patents

Composicion fluida injectable que comprende al menos un polimero termoplastico biodegradable, un liquido organico aprotico polar biocompatible y buprenorfina, donde la composicion es transformada in situ en un implante solido por contacto con agua u otro medio; método para prepararla; implante y kit.

Info

Publication number
CL2012003462A1
CL2012003462A1 CL2012003462A CL2012003462A CL2012003462A1 CL 2012003462 A1 CL2012003462 A1 CL 2012003462A1 CL 2012003462 A CL2012003462 A CL 2012003462A CL 2012003462 A CL2012003462 A CL 2012003462A CL 2012003462 A1 CL2012003462 A1 CL 2012003462A1
Authority
CL
Chile
Prior art keywords
implant
composition
buprenorphine
situ
kit
Prior art date
Application number
CL2012003462A
Other languages
English (en)
Spanish (es)
Inventor
Richard L Norton
Andrew Watkins
Mingxing Zhou
Original Assignee
Rb Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42471306&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012003462(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rb Pharmaceuticals Ltd filed Critical Rb Pharmaceuticals Ltd
Publication of CL2012003462A1 publication Critical patent/CL2012003462A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2012003462A 2010-06-08 2012-12-07 Composicion fluida injectable que comprende al menos un polimero termoplastico biodegradable, un liquido organico aprotico polar biocompatible y buprenorfina, donde la composicion es transformada in situ en un implante solido por contacto con agua u otro medio; método para prepararla; implante y kit. CL2012003462A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1009549.5A GB2481018B (en) 2010-06-08 2010-06-08 Injectable flowable composition comprising buprenorphine

Publications (1)

Publication Number Publication Date
CL2012003462A1 true CL2012003462A1 (es) 2013-04-01

Family

ID=42471306

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012003462A CL2012003462A1 (es) 2010-06-08 2012-12-07 Composicion fluida injectable que comprende al menos un polimero termoplastico biodegradable, un liquido organico aprotico polar biocompatible y buprenorfina, donde la composicion es transformada in situ en un implante solido por contacto con agua u otro medio; método para prepararla; implante y kit.

Country Status (32)

Country Link
US (1) US8921387B2 (cg-RX-API-DMAC7.html)
EP (3) EP2579874B1 (cg-RX-API-DMAC7.html)
JP (2) JP5986072B2 (cg-RX-API-DMAC7.html)
KR (1) KR101865689B1 (cg-RX-API-DMAC7.html)
CN (1) CN103079544B (cg-RX-API-DMAC7.html)
AU (1) AU2011263478B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012031290A2 (cg-RX-API-DMAC7.html)
CA (1) CA2801676C (cg-RX-API-DMAC7.html)
CL (1) CL2012003462A1 (cg-RX-API-DMAC7.html)
CO (1) CO6670529A2 (cg-RX-API-DMAC7.html)
CY (1) CY1120761T1 (cg-RX-API-DMAC7.html)
DK (2) DK2579874T3 (cg-RX-API-DMAC7.html)
ES (2) ES2656938T3 (cg-RX-API-DMAC7.html)
FI (1) FI3360538T3 (cg-RX-API-DMAC7.html)
GB (2) GB2481018B (cg-RX-API-DMAC7.html)
HR (1) HRP20180118T1 (cg-RX-API-DMAC7.html)
HU (1) HUE038275T2 (cg-RX-API-DMAC7.html)
IL (2) IL223488A (cg-RX-API-DMAC7.html)
LT (1) LT2579874T (cg-RX-API-DMAC7.html)
MX (1) MX339209B (cg-RX-API-DMAC7.html)
MY (1) MY171625A (cg-RX-API-DMAC7.html)
NO (1) NO2579874T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ604026A (cg-RX-API-DMAC7.html)
PL (1) PL2579874T3 (cg-RX-API-DMAC7.html)
PT (1) PT2579874T (cg-RX-API-DMAC7.html)
RS (1) RS56820B1 (cg-RX-API-DMAC7.html)
RU (1) RU2607498C2 (cg-RX-API-DMAC7.html)
SG (1) SG186200A1 (cg-RX-API-DMAC7.html)
SI (1) SI2579874T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201800038T1 (cg-RX-API-DMAC7.html)
WO (1) WO2011154724A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201209233B (cg-RX-API-DMAC7.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8470359B2 (en) * 2000-11-13 2013-06-25 Qlt Usa, Inc. Sustained release polymer
GB2481018B (en) 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
WO2013126552A1 (en) 2012-02-21 2013-08-29 Auburn University Buprenorphine nanoparticle composition and methods thereof
NZ631539A (en) 2012-04-17 2016-10-28 Purdue Pharma Lp Systems and methods for treating an opioid-induced adverse pharmacodynamic response
MX387722B (es) 2012-07-26 2025-03-18 Camurus Ab Formulaciones de opioides.
SI2877155T1 (sl) 2012-07-26 2021-04-30 Camurus Ab Opioidne formulacije
EP2931253A1 (en) * 2012-12-13 2015-10-21 Heron Therapeutics, Inc. Pharmaceutical composition comprising antiemetic compounds and polyorthoester
US9393211B2 (en) * 2013-03-15 2016-07-19 Oakwood Laboratories LLC High drug load buprenorphine microspheres and method of producing same
KR102505642B1 (ko) * 2013-03-15 2023-03-06 헤론 테라퓨틱스 인코포레이티드 폴리오르토에스테르 및 비프로톤성 용매의 조성물
US9636308B2 (en) 2013-03-15 2017-05-02 Oakwood Laboratories LLC High drug load buprenorphine microspheres and method of producing same
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
EP3509601A1 (en) 2014-04-21 2019-07-17 Heron Therapeutics, Inc. A pharmaceutical composition comprising a delivery system, an amide-type local anesthetic, and meloxicam
EP3785700A1 (en) * 2014-04-21 2021-03-03 Heron Therapeutics, Inc. Compositions of a polyorthoester and an organic acid excipient
KR20220138419A (ko) 2014-04-21 2022-10-12 헤론 테라퓨틱스 인코포레이티드 장기간 작용하는 중합체 전달 시스템
US9801945B2 (en) 2014-04-21 2017-10-31 Heron Therapeutics, Inc. Long-acting polymeric delivery systems
JP6568102B2 (ja) 2014-04-28 2019-08-28 オーフォームド,インコーポレイティド ブプレノルフィン二量体及び消化管疾患の治療におけるその使用
GB201419091D0 (en) 2014-10-27 2014-12-10 Camurus Ab Formulations
ES2808150T3 (es) * 2014-11-07 2021-02-25 Indivior Uk Ltd Regímenes de dosificación de buprenorfina
KR102696721B1 (ko) * 2015-08-03 2024-08-19 톨마 인터내셔날 리미티드 약물의 장기간 지속적인 투여를 위한 액체 폴리머 전달 시스템
AU2016355236C1 (en) 2015-11-16 2022-09-22 Medincell A method for morselizing and/or targeting pharmaceutically active principles to synovial tissue
FI3512518T3 (fi) * 2016-09-13 2023-01-31 Hitaasti vapautuvia buprenorfiiniformulaatioita
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
AU2018283724B2 (en) 2017-06-16 2021-08-19 Indivior Uk Limited Methods to treat opioid use disorder
CN112236142A (zh) 2018-01-22 2021-01-15 逸达生物科技股份有限公司 用于缓释递送丁丙诺啡的药物组合物
NZ766474A (en) * 2018-05-11 2023-03-31 Alar Pharmaceuticals Inc Long-acting injectable formulations and crystalline forms of buprenorphine derivatives
AU2019357036B2 (en) 2018-10-11 2024-11-14 Indivior Uk Limited Buprenorphine to treat respiratory depression
US12403291B2 (en) 2019-08-30 2025-09-02 Intersect Ent, Inc. Submucosal bioresorbable drug eluting platform
CN118831057A (zh) * 2023-04-25 2024-10-25 深圳善康医药科技股份有限公司 丁丙诺啡植入剂及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
CA2582666C (en) 1994-04-08 2010-05-25 Qlt Usa, Inc. Controlled release implant
US20030211157A1 (en) * 1996-05-06 2003-11-13 Simon David Lew Semi-sol delivery blend for water soluble molecules
US6143314A (en) * 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6461631B1 (en) 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
NZ536965A (en) * 2002-05-31 2007-02-23 Titan Pharmaceuticals Inc Nonerodible polymeric matrix with buprenorphine encapsulated for the treatment of opiate addiction and pain
PL377333A1 (pl) * 2002-11-06 2006-01-23 Alza Corporation Preparaty depot o kontrolowanym uwalnianiu
EP1622540A4 (en) * 2003-03-11 2009-12-30 Qlt Usa Inc PREPARATIONS OF ANTI-CANCER AGENTS DEPENDENT ON THE CELLULAR PROGRAM
MX2007003789A (es) * 2004-10-04 2007-07-20 Qlt Usa Inc Suministro ocular de formulaciones polimericas para suministro.
RS53890B1 (sr) * 2004-11-10 2015-08-31 Tolmar Therapeutics, Inc. Stabilizovan polimerni sistem za isporuku
ES2550014T3 (es) 2007-02-15 2015-11-03 Tolmar Therapeutics, Inc. Poli-(lactida/glicolida) de descarga lenta y métodos para producir polímeros
US20090181068A1 (en) * 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
GB2481018B (en) 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine

Also Published As

Publication number Publication date
JP2016155865A (ja) 2016-09-01
PT2579874T (pt) 2018-01-29
FI3360538T3 (fi) 2023-03-22
MX2012014335A (es) 2013-03-05
ES2939612T3 (es) 2023-04-25
WO2011154724A3 (en) 2012-07-12
CO6670529A2 (es) 2013-05-15
ZA201209233B (en) 2014-04-30
SMT201800038T1 (it) 2018-03-08
GB2481018A (en) 2011-12-14
GB201009549D0 (en) 2010-07-21
GB201413064D0 (en) 2014-09-03
EP3360538B1 (en) 2023-02-15
PL2579874T3 (pl) 2018-05-30
GB2481018B (en) 2015-03-18
CA2801676A1 (en) 2011-12-15
IL223488A (en) 2017-10-31
EP4218720A1 (en) 2023-08-02
MX339209B (es) 2016-04-15
RU2012157244A (ru) 2014-07-20
HUE038275T2 (hu) 2018-10-29
EP2579874A2 (en) 2013-04-17
BR112012031290A2 (pt) 2016-11-01
SG186200A1 (en) 2013-01-30
MY171625A (en) 2019-10-21
EP3360538A1 (en) 2018-08-15
RU2607498C2 (ru) 2017-01-10
ES2656938T3 (es) 2018-03-01
KR101865689B1 (ko) 2018-06-08
DK2579874T3 (da) 2018-01-29
CY1120761T1 (el) 2019-12-11
EP2579874B1 (en) 2018-01-10
AU2011263478B2 (en) 2015-01-22
CA2801676C (en) 2018-08-07
AU2011263478A1 (en) 2013-01-10
WO2011154724A2 (en) 2011-12-15
JP5986072B2 (ja) 2016-09-06
SI2579874T1 (en) 2018-03-30
KR20130135026A (ko) 2013-12-10
DK3360538T3 (da) 2023-03-06
US20130210853A1 (en) 2013-08-15
CN103079544A (zh) 2013-05-01
JP6251774B2 (ja) 2017-12-20
WO2011154724A9 (en) 2012-08-16
CN103079544B (zh) 2017-06-09
HRP20180118T1 (hr) 2018-03-09
RS56820B1 (sr) 2018-04-30
NZ604026A (en) 2015-01-30
JP2013533230A (ja) 2013-08-22
LT2579874T (lt) 2018-02-12
GB2513267B (en) 2015-03-18
GB2513267A (en) 2014-10-22
US8921387B2 (en) 2014-12-30
NO2579874T3 (cg-RX-API-DMAC7.html) 2018-06-09
IL254417A0 (en) 2017-11-30

Similar Documents

Publication Publication Date Title
CL2012003462A1 (es) Composicion fluida injectable que comprende al menos un polimero termoplastico biodegradable, un liquido organico aprotico polar biocompatible y buprenorfina, donde la composicion es transformada in situ en un implante solido por contacto con agua u otro medio; método para prepararla; implante y kit.
AR071297A1 (es) Sistemas de fluidos limpios para fracturacion de monocapa parcial
AR081395A1 (es) Hidroxido de carbonato de lantano oxicarbonato de lantano y metodos para su manufactura y uso
BRPI1015966A2 (pt) "método para tratar uma formação subterrânea, e, meio de armazenamento legível por computador."
BRPI0915432A2 (pt) célula de eletrólise, e, método para eletrolisar um líquido.
BR112012002608A2 (pt) composição lubrificante, e, método para melhorar o desempenho de uma composição lubrificante.
BRPI1014319A2 (pt) sistema para minimizar perda de circulação associada com a operação de um reservatório subterrâneo, e, método implementado por computador.
BR112014016408A2 (pt) método para perfuração em uma formação subterrânea, e, fluido de perfuração
DK2310670T3 (da) Bærekonstruktion til anvendelse i offshore vindfarmindustrien
BRPI0811319A2 (pt) Composição fluida, método de formação de uma composição fluida, implante biodegrádavel formado in situ, método de formação de um implante biodegradável in situ, kit, implante e método de trataento
CL2008002066A1 (es) Metodo para estimar probabilidad de duracion de excavadoras mineras electricas sobre la base de cargas acumulativas de cucharones dentados.
BR112012002984A2 (pt) estrutura e método de ancoragem final para corpo de filamento de plástico reforçado com fibra.
PL2319806T3 (pl) Armatura odpływu wody zawierająca ogniwo elektrochemiczne i sposób jej eksploatacji
BR112012032962A2 (pt) composição para utilização em um furo de poço, composição em gel para utilização em um furo de poço, e método.
BRPI0922294A2 (pt) método para o monitoramento do desgaste de brocas cortadoras de rochas.
IN2014CN03185A (cg-RX-API-DMAC7.html)
BRPI0921903A2 (pt) máquina de lavar louças, e, tanque de água para uma máquina de lavar louças
MX2013011607A (es) Masilla osea.
BRPI1005505A2 (pt) estrutura de bomba hidráulica para um gerador de turbina eólica ou um gerador de corrente de maré, e, método para montar uma bomba hidráulica do gerador de turbina eólica ou do gerador de corrente de maré.
BRPI0917728A2 (pt) composição, uso da composição, e, método de prevenção da formação de espuma em uma composição
AR087483A1 (es) Carbonato de calcio con tratamiento de superficie para la union y biorremediacion de composiciones que contienen hidrocarburos
BRPI1014355A2 (pt) método para determinar umidificabilidade de uma zona de formação de solo em torno de um poço.
PL2732157T3 (pl) Elastyczne, hydrauliczne lub pneumatyczne łożysko z akumulatorem ciśnienia oraz jego zastosowanie w turbinach wiatrowych
BRPI1015969A2 (pt) "método para determinar a capacidade de uma composição de cimento para suportar as condições de formação subterrânea."
DK2419572T3 (da) Fremgangsmåde til injektion af overfladevand i jorden